Cargando…

Morphology-Voltage-P-wave-duration (MVP) score to select patients for continuous atrial fibrillation screening to prevent stroke

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Foundation. Main funding source(s): The LOOP Study was funded by Innovation Fund Denmark [grant number 12-1352259], The Research Foundation for the Capital Region of Denmark, The Danish Heart Foundation [grant number 11-04-R83-A3363-22625], Aalborg...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, L Y, Diederichsen, S Z, Hojberg, S, Krieger, D W, Graff, C, Olesen, M S, Nielsen, J B, Brandes, A, Kober, L, Haugan, K J, Svendsen, J H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207139/
http://dx.doi.org/10.1093/europace/euad122.199
_version_ 1785046384584425472
author Xing, L Y
Diederichsen, S Z
Hojberg, S
Krieger, D W
Graff, C
Olesen, M S
Nielsen, J B
Brandes, A
Kober, L
Haugan, K J
Svendsen, J H
author_facet Xing, L Y
Diederichsen, S Z
Hojberg, S
Krieger, D W
Graff, C
Olesen, M S
Nielsen, J B
Brandes, A
Kober, L
Haugan, K J
Svendsen, J H
author_sort Xing, L Y
collection PubMed
description FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Foundation. Main funding source(s): The LOOP Study was funded by Innovation Fund Denmark [grant number 12-1352259], The Research Foundation for the Capital Region of Denmark, The Danish Heart Foundation [grant number 11-04-R83-A3363-22625], Aalborg University Talent Management Program, Arvid Nilssons Fond, Skibsreder Per Henriksen, R og Hustrus Fond, the European Union’s Horizon 2020 program [grant number 847770], Læge Sophus Carl Emil Friis og hustru Olga Doris Friis’ Legat, and an unrestricted grant from Medtronic. BACKGROUND: It is well known that atrial fibrillation (AF) confers a substantially increased risk of ischemic stroke, but data on health benefits from AF screening are scarce. The newly proposed MVP risk score combining the duration, voltage and morphology of P-wave has been demonstrated to be predictive of AF and might therefore also be useful in risk-stratifying individuals for AF screening and subsequent treatment. PURPOSE: The present study sought to examine MVP risk score and its P-wave components for prediction of AF screening effects. METHODS: The LOOP Study randomized AF-naïve individuals aged 70-90 years with additional stroke risk factors to either continuous AF screening with implantable loop recorder (ILR) and subsequent anticoagulation initiation upon detection of AF episode ≥6 minutes, or usual care. In this secondary analysis, the LOOP participants with a baseline 12-lead electrocardiogram (ECG) suitable for P-wave measurement were included. RESULTS: Of 5759 participants included, 265 (4.6%) had had ischemic stroke during follow-up: 213 (4.9%) of 4311 in the control group versus 64 (3.6%) of 1448 in the ILR group. Among the participants in the control group, a significantly increased risk of ischemic stroke was observed for MVP score 5-6 versus score 0-2 (hazard ratio (HR) 1.66 [95% confidence interval (CI): 1.01-2.75]) and for the presence of interatrial block (IAB) versus no IAB (HR 1.85 [95% CI: 1.19-2.86]), whereas a P-wave voltage in lead I (PWVI) <100 µV was associated with risk reduction compared to higher voltage (HR 0.65 [95% CI: 0.45-0.93]). Further spline analysis revealed longer P-wave duration (PWD) to also be correlated with higher stroke risk (HR 1.49 [95% CI: 1.11-2.00] for >110 versus ≤110 ms). Compared with usual care, ILR screening did not significantly reduce the stroke risk regardless of MVP risk score, PWD, PWVI, or IAB pattern at baseline. CONCLUSIONS: In an elderly population with additional stroke risk factors, both the P-wave parameters and the combined MVP risk score based on 12-lead ECG were associated with ischemic stroke, but these did not successfully demonstrate an association with effects of AF screening on stroke prevention. [Figure: see text] [Figure: see text]
format Online
Article
Text
id pubmed-10207139
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102071392023-05-25 Morphology-Voltage-P-wave-duration (MVP) score to select patients for continuous atrial fibrillation screening to prevent stroke Xing, L Y Diederichsen, S Z Hojberg, S Krieger, D W Graff, C Olesen, M S Nielsen, J B Brandes, A Kober, L Haugan, K J Svendsen, J H Europace 10.5 - Stroke Prevention FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Foundation. Main funding source(s): The LOOP Study was funded by Innovation Fund Denmark [grant number 12-1352259], The Research Foundation for the Capital Region of Denmark, The Danish Heart Foundation [grant number 11-04-R83-A3363-22625], Aalborg University Talent Management Program, Arvid Nilssons Fond, Skibsreder Per Henriksen, R og Hustrus Fond, the European Union’s Horizon 2020 program [grant number 847770], Læge Sophus Carl Emil Friis og hustru Olga Doris Friis’ Legat, and an unrestricted grant from Medtronic. BACKGROUND: It is well known that atrial fibrillation (AF) confers a substantially increased risk of ischemic stroke, but data on health benefits from AF screening are scarce. The newly proposed MVP risk score combining the duration, voltage and morphology of P-wave has been demonstrated to be predictive of AF and might therefore also be useful in risk-stratifying individuals for AF screening and subsequent treatment. PURPOSE: The present study sought to examine MVP risk score and its P-wave components for prediction of AF screening effects. METHODS: The LOOP Study randomized AF-naïve individuals aged 70-90 years with additional stroke risk factors to either continuous AF screening with implantable loop recorder (ILR) and subsequent anticoagulation initiation upon detection of AF episode ≥6 minutes, or usual care. In this secondary analysis, the LOOP participants with a baseline 12-lead electrocardiogram (ECG) suitable for P-wave measurement were included. RESULTS: Of 5759 participants included, 265 (4.6%) had had ischemic stroke during follow-up: 213 (4.9%) of 4311 in the control group versus 64 (3.6%) of 1448 in the ILR group. Among the participants in the control group, a significantly increased risk of ischemic stroke was observed for MVP score 5-6 versus score 0-2 (hazard ratio (HR) 1.66 [95% confidence interval (CI): 1.01-2.75]) and for the presence of interatrial block (IAB) versus no IAB (HR 1.85 [95% CI: 1.19-2.86]), whereas a P-wave voltage in lead I (PWVI) <100 µV was associated with risk reduction compared to higher voltage (HR 0.65 [95% CI: 0.45-0.93]). Further spline analysis revealed longer P-wave duration (PWD) to also be correlated with higher stroke risk (HR 1.49 [95% CI: 1.11-2.00] for >110 versus ≤110 ms). Compared with usual care, ILR screening did not significantly reduce the stroke risk regardless of MVP risk score, PWD, PWVI, or IAB pattern at baseline. CONCLUSIONS: In an elderly population with additional stroke risk factors, both the P-wave parameters and the combined MVP risk score based on 12-lead ECG were associated with ischemic stroke, but these did not successfully demonstrate an association with effects of AF screening on stroke prevention. [Figure: see text] [Figure: see text] Oxford University Press 2023-05-24 /pmc/articles/PMC10207139/ http://dx.doi.org/10.1093/europace/euad122.199 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle 10.5 - Stroke Prevention
Xing, L Y
Diederichsen, S Z
Hojberg, S
Krieger, D W
Graff, C
Olesen, M S
Nielsen, J B
Brandes, A
Kober, L
Haugan, K J
Svendsen, J H
Morphology-Voltage-P-wave-duration (MVP) score to select patients for continuous atrial fibrillation screening to prevent stroke
title Morphology-Voltage-P-wave-duration (MVP) score to select patients for continuous atrial fibrillation screening to prevent stroke
title_full Morphology-Voltage-P-wave-duration (MVP) score to select patients for continuous atrial fibrillation screening to prevent stroke
title_fullStr Morphology-Voltage-P-wave-duration (MVP) score to select patients for continuous atrial fibrillation screening to prevent stroke
title_full_unstemmed Morphology-Voltage-P-wave-duration (MVP) score to select patients for continuous atrial fibrillation screening to prevent stroke
title_short Morphology-Voltage-P-wave-duration (MVP) score to select patients for continuous atrial fibrillation screening to prevent stroke
title_sort morphology-voltage-p-wave-duration (mvp) score to select patients for continuous atrial fibrillation screening to prevent stroke
topic 10.5 - Stroke Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207139/
http://dx.doi.org/10.1093/europace/euad122.199
work_keys_str_mv AT xingly morphologyvoltagepwavedurationmvpscoretoselectpatientsforcontinuousatrialfibrillationscreeningtopreventstroke
AT diederichsensz morphologyvoltagepwavedurationmvpscoretoselectpatientsforcontinuousatrialfibrillationscreeningtopreventstroke
AT hojbergs morphologyvoltagepwavedurationmvpscoretoselectpatientsforcontinuousatrialfibrillationscreeningtopreventstroke
AT kriegerdw morphologyvoltagepwavedurationmvpscoretoselectpatientsforcontinuousatrialfibrillationscreeningtopreventstroke
AT graffc morphologyvoltagepwavedurationmvpscoretoselectpatientsforcontinuousatrialfibrillationscreeningtopreventstroke
AT olesenms morphologyvoltagepwavedurationmvpscoretoselectpatientsforcontinuousatrialfibrillationscreeningtopreventstroke
AT nielsenjb morphologyvoltagepwavedurationmvpscoretoselectpatientsforcontinuousatrialfibrillationscreeningtopreventstroke
AT brandesa morphologyvoltagepwavedurationmvpscoretoselectpatientsforcontinuousatrialfibrillationscreeningtopreventstroke
AT koberl morphologyvoltagepwavedurationmvpscoretoselectpatientsforcontinuousatrialfibrillationscreeningtopreventstroke
AT haugankj morphologyvoltagepwavedurationmvpscoretoselectpatientsforcontinuousatrialfibrillationscreeningtopreventstroke
AT svendsenjh morphologyvoltagepwavedurationmvpscoretoselectpatientsforcontinuousatrialfibrillationscreeningtopreventstroke